Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial
Wilding, J P H × Charpentier, G Hollander, P González-Gálvez, G Mathieu, Chantal Vercruysse, F Usiskin, K Law, G Black, S Canovatchel, W Meininger, G #
International Journal of Clinical Practice vol:67 issue:12 pages:1267-82
Canagliflozin is a sodium glucose co-transporter 2 inhibitor developed for the treatment of type 2 diabetes mellitus (T2DM). This randomised, double-blind, placebo-controlled, Phase 3 study evaluated the efficacy and safety of canagliflozin as an add-on to metformin plus sulphonylurea in patients with T2DM.